Non-PCI/CABG therapies for refractory angina.

Ki E Park, C Richard Conti

Journal: Trends in cardiovascular medicine 2018;28(3):223-228

PMID: 29157949

Abstract

Angina persists for many patients despite modern medical therapy and/or revascularization, and this is referred to as refractory angina. All patients with refractory angina must be treated with aggressive risk factor modification plus optimized medical management. β-Blockers and nitrates are usually first-line agents; however most patients require multiple medications for refractory symptom control. Novel agents, such as ranolazine and ivabradine, as well as non-pharmacologic therapies, such as enhanced external counterpulsation and cardiac rehabilitation, may provide relief or reduction of angina. Other standard treatments such as antiplatelet therapy, lipid reduction therapy, blood pressure control, diabetes control, smoking cessation, and wei1ght control should be part of the management of refractory angina as well.

Copyright © 2018 Elsevier Inc. All rights reserved.

Address: Division of Cardiovascular Medicine, College of Medicine, University of Florida, Gainesville, FL; Department of Cardiology, Malcom Randall VA Medical Center, North Florida/South Georgia Veterans Health System, Gainesville, FL.; Division of Cardiovascular Medicine, College of Medicine, University of Florida, Gainesville, FL. Electronic address: [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.